NASDAQ
KALV

Kalvista Pharmaceuticals Inc

Biotechnology
Healthcare

Prices are adjusted according to historical splits.

Kalvista Pharmaceuticals Inc Stock Price

Vitals

Today's Low:
$10.1902
Today's High:
$10.6
Open Price:
$10.5
52W Low:
$4.12
52W High:
$15.5
Prev. Close:
$10.54
Volume:
179261

Company Statistics

Market Cap.:
$362.61 million
Book Value:
4.066
Revenue TTM:
$3.82 million
Operating Margin TTM:
0%
Gross Profit TTM:
$-80276000
Profit Margin:
0%
Return on Assets TTM:
-35.7%
Return on Equity TTM:
-62.64%

Company Profile

Kalvista Pharmaceuticals Inc had its IPO on 2015-04-09 under the ticker symbol KALV.

The company operates in the Healthcare sector and Biotechnology industry. Kalvista Pharmaceuticals Inc has a staff strength of 118 employees.

Stock update

Shares of Kalvista Pharmaceuticals Inc opened at $10.5 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $10.19 - $10.6, and closed at $10.32.

This is a -2.09% slip from the previous day's closing price.

A total volume of 179,261 shares were traded at the close of the day’s session.

In the last one week, shares of Kalvista Pharmaceuticals Inc have slipped by -3.19%.

Kalvista Pharmaceuticals Inc's Key Ratios

Kalvista Pharmaceuticals Inc has a market cap of $362.61 million, indicating a price to book ratio of 0.9792 and a price to sales ratio of 107.4168.

In the last 12-months Kalvista Pharmaceuticals Inc’s revenue was $3.82 million with a gross profit of $-80276000 and an EBITDA of $-97114000. The EBITDA ratio measures Kalvista Pharmaceuticals Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Kalvista Pharmaceuticals Inc’s operating margin was 0% while its return on assets stood at -35.7% with a return of equity of -62.64%.

In Q2.3333333333333, Kalvista Pharmaceuticals Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 30.7%.

Kalvista Pharmaceuticals Inc’s PE and PEG Ratio

Forward PE
0
Trailing PE
0
PEG
0

Its diluted EPS in the last 12-months stands at $-3.24 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Kalvista Pharmaceuticals Inc’s profitability.

Kalvista Pharmaceuticals Inc stock is trading at a EV to sales ratio of 76.3323 and a EV to EBITDA ratio of -0.2456. Its price to sales ratio in the trailing 12-months stood at 107.4168.

Kalvista Pharmaceuticals Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$160.33 million
Total Liabilities
$14.13 million
Operating Cash Flow
$0
Capital Expenditure
$6000
Dividend Payout Ratio
0%

Kalvista Pharmaceuticals Inc ended 2024 with $160.33 million in total assets and $0 in total liabilities. Its intangible assets were valued at $160.33 million while shareholder equity stood at $139.34 million.

Kalvista Pharmaceuticals Inc ended 2024 with $0 in deferred long-term liabilities, $14.13 million in other current liabilities, in common stock, $-368399000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $49.41 million and cash and short-term investments were $123.26 million. The company’s total short-term debt was $1,122,000 while long-term debt stood at $0.

Kalvista Pharmaceuticals Inc’s total current assets stands at $149.84 million while long-term investments were $0 and short-term investments were $73.85 million. Its net receivables were $0 compared to accounts payable of $5.06 million and inventory worth $0.

In 2024, Kalvista Pharmaceuticals Inc's operating cash flow was $0 while its capital expenditure stood at $6000.

Comparatively, Kalvista Pharmaceuticals Inc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$10.32
52-Week High
$15.5
52-Week Low
$4.12
Analyst Target Price
$20.67

Kalvista Pharmaceuticals Inc stock is currently trading at $10.32 per share. It touched a 52-week high of $15.5 and a 52-week low of $15.5. Analysts tracking the stock have a 12-month average target price of $20.67.

Its 50-day moving average was $10.34 and 200-day moving average was $8.48 The short ratio stood at 21.37 indicating a short percent outstanding of 0%.

Around 97.1% of the company’s stock are held by insiders while 10007.7% are held by institutions.

Frequently Asked Questions About Kalvista Pharmaceuticals Inc

The stock symbol (also called stock or share ticker) of Kalvista Pharmaceuticals Inc is KALV

The IPO of Kalvista Pharmaceuticals Inc took place on 2015-04-09

Similar Industry Stocks (Biotechnology)

Last Price
Chg
Chg%
$3.31
-0.01
-0.3%
$1.42
0.12
+9.23%
$61.31
0.1
+0.16%
$6.11
-0.97
-13.71%
$17.72
0.02
+0.11%
$0.64
-0.03
-4.48%
$6.95
-0.1
-1.42%
$599.2
-16.25
-2.64%
$724.55
-2.55
-0.35%
$401.6
-7.9
-1.93%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with unmet needs in the United States. The company’s product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include sebetralstat, which is initiation of the Phase 3 KONFIDENT trial as a potential oral, on-demand therapy for HAE attacks; and Factor XIIa, an oral inhibitor program which is in preclinical stage targets an enzyme in HAE. The company is headquartered in Cambridge, Massachusetts.

Address

55 Cambridge Parkway, Cambridge, MA, United States, 02142